Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …

Guidelines for the management of chemotherapy-induced emesis are necessary to help
clinicians match the emetogenicity of antineoplastic agents with the abundance of antiemetic …

Aim: We compare neurokinin-1 receptor antagonist (NK-1RA)-based triple regimen and
conventional duplex regimen for antiemetic efficacy for patients with moderately emetogenic …

Purpose: Prevention of chemotherapy-induced nausea and vomiting is essential to preserve
quality of life in patients with cancer receiving highly emetogenic chemotherapy (HEC) …

OBJECTIVE To determine the prevalence of substandard antiemetic therapy among recently
published trials conducted in patients with cancer who received emetogenic chemotherapy …

The objective of the present study was to examine the problem of the control of nausea and
vomiting induced by non-cisplatin containing cyclophosphamide-based chemotherapy …

Background: Triple antiemetic therapy, such as a 5-HT3 receptor antagonist (5H3-RA),
aprepitant and dexamethasone, is recommended for the prophylaxis of highly emetogenic …

9111 Background: Serotonin antagonists, NK-1 antagonists (NKA) and corticosteroids (C)
have all shown efficacy against chemotherapy-induced nausea and vomiting. However …

Guidelines recommend a combination of a 5-HT 3-receptor antagonist, dexamethasone, and
an NK 1-receptor antagonist in HEC and carboplatin-based chemotherapy. The addition of …

Purpose Although risk factors related to chemotherapy-induced nausea and vomiting (CINV)
have been identified in previous studies, only a few studies have evaluated the risk factors …